Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Operating Expenses for 2 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $16.8 million; the TTM value through Mar 2026 reached $16.8 million, up 1273.69%, while the annual FY2024 figure was $1.2 million, N/A changed from the prior year.
  • Other Operating Expenses hit $16.8 million in Q4 2025 for Crescent Biopharma, up from $1.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $16.8 million in Q4 2025 and bottomed at $1.2 million in Q3 2024.